The drug is designed to target a mutated form of a gene known as KRAS that occurs in about 13% of non-small cell lung cancers, the most common form of the disease. Earlier in October, Bristol Myers Squibb had agreed to buy Mirati for up to $5.8 billion, to diversify its oncology business with Krazati.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment